WO2013146685A1 - 吸収性物品 - Google Patents

吸収性物品 Download PDF

Info

Publication number
WO2013146685A1
WO2013146685A1 PCT/JP2013/058590 JP2013058590W WO2013146685A1 WO 2013146685 A1 WO2013146685 A1 WO 2013146685A1 JP 2013058590 W JP2013058590 W JP 2013058590W WO 2013146685 A1 WO2013146685 A1 WO 2013146685A1
Authority
WO
WIPO (PCT)
Prior art keywords
chain hydrocarbon
acid
top sheet
hydrocarbon moiety
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2013/058590
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
竜也 田村
野田　祐樹
貴志 野本
卓 小野塚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unicharm Corp
Original Assignee
Unicharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicharm Corp filed Critical Unicharm Corp
Publication of WO2013146685A1 publication Critical patent/WO2013146685A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47—Sanitary towels, incontinence pads or napkins
    • A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47—Sanitary towels, incontinence pads or napkins
    • A61F13/475—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means
    • A61F13/4751—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction
    • A61F13/4756—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction the means consisting of grooves, e.g. channels, depressions or embossments, resulting in a heterogeneous surface level
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/512—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations

Definitions

  • the present invention relates to absorbent articles such as sanitary napkins, panty liners, incontinence pads, and incontinence liners.
  • An absorbent article obtained by applying a skin care composition to a top sheet of a main part is known as a conventional technique (for example, Patent Document 1).
  • An apertured molded film is used for the top sheet of the absorbent article.
  • the absorbent article is provided with a flap formed by extending the top sheet in the width direction.
  • the skin care composition applied to the top sheet of the main body part is an open part of the top sheet in the folded wing part. It may penetrate into the wing through.
  • the permeated skin care composition weakens the bonding between the top sheet and the back sheet in the wing part, and the top sheet may peel from the back sheet when the absorbent article is used for a long time.
  • An object of the present invention is to provide an absorbent article in which the composition applied to the top sheet of the main body part permeates into the wing part to prevent the sheet constituting the wing part from peeling off.
  • the present invention employs the following configuration in order to solve the above problems. That is, the present invention has a longitudinal direction and a width direction, a liquid-permeable top sheet provided on the skin side, a liquid-impermeable back sheet provided on the clothing side, and between the top sheet and the back sheet.
  • An absorbent article comprising: a main body portion provided with a liquid-retaining absorbent body provided in a pair; and a pair of wing portions including a top sheet and a back sheet extending in a width direction from both side edges of the main body portion.
  • the top sheet of the main body includes a composition application layer in which a predetermined composition is applied to an excretion opening contact area that contacts at least the wearer's excretion opening on the skin side surface, and the top sheet is a resin film. Yes, the top sheet has an opening at least in the excretory opening contact area, does not have an opening in the wing, and the top sheet has a protrusion in the wing.
  • Another aspect of the present invention has a longitudinal direction and a width direction, a liquid-permeable top sheet provided on the skin side, a liquid-impermeable back sheet provided on the clothing side, and between the top sheet and the back sheet.
  • a liquid retainer provided on the main body, and a main body provided with a pair of side sheets disposed on both sides of the top sheet, and a side sheet and a back sheet extending in the width direction from both side edges of the main body.
  • An absorbent article including a pair of wing parts, wherein the top sheet is a composition application in which a predetermined composition is applied to at least an excretion opening contact area in contact with the wearer's excretion opening on the skin side surface.
  • the side sheet is a resin film, and the side sheet does not have an opening in the wing portion and includes a protrusion.
  • the present invention it is possible to prevent the sheet constituting the wing part from peeling off when the composition applied to the top sheet of the main body part penetrates the wing part.
  • FIG. 1 is a partially broken plan view of an embodiment of an absorbent article of the present invention.
  • FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG.
  • FIG. 3 shows a first mountain fold portion formed on the outer region of both side surfaces in the width direction of the absorbent body and the top sheet of the wing portion in the top sheet of the main body portion of the absorbent article of one embodiment of the present invention, It is a figure for demonstrating the 2 mountain fold part and a valley fold part.
  • Drawing 4 is a figure for explaining the 1st mountain fold part, the 2nd mountain fold part, and valley fold part formed in the excretion mouth contact area in the absorptive article of one embodiment of the present invention.
  • FIG. 5 is a figure for explaining an absorptive article of one embodiment of the present invention by which a wing part was folded up for packaging.
  • FIG. 6 is a perspective view of a packaged product including an absorbent article according to an embodiment of the present invention.
  • FIG. 7 is a schematic cross-sectional view showing a cross section along the line DD of FIG.
  • FIG. 8 is a diagram for explaining a method for manufacturing an absorbent article according to an embodiment of the present invention.
  • Drawing 9 is a figure for explaining the crevice formation roll used for manufacture of the absorptive article of one embodiment of the present invention.
  • FIG. 10 is a diagram for explaining a region where a recess is formed by a recess forming roll in the topsheet.
  • Drawing 11 is a figure for explaining the upper stage roll of the extension gear roll used for manufacture of the absorptive article of one embodiment of the present invention.
  • Drawing 12 is a figure for explaining the lower stage roll of the extension gear roll used for manufacture of the absorptive article of one embodiment of the present invention.
  • FIG. 13 is a diagram for explaining a top sheet for a sheet stretched by a stretching gear roll.
  • FIG. 14 is a plan view of a modification of one embodiment of the absorbent article of the present invention.
  • FIG. 15 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin in which the top sheet contains tri-C2L oil fatty acid glycerides.
  • FIG. 16 is a photomicrograph of menstrual blood with or without a blood modifying agent.
  • FIG. 17 is a diagram for explaining a method of measuring the surface tension.
  • FIG. 1 is a partially broken plan view of an absorbent article according to an embodiment of the present invention
  • FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG.
  • the absorbent article 1 includes a liquid-permeable top sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 and a top sheet provided on the clothing side (non-skin contact side). 2 and a back sheet 3, and a pair of a top sheet 2 and a back sheet 3 that extend in the width direction from both side edges of the main body 10.
  • the wing part 6 of this is included.
  • Reference numeral 61 denotes a root of the wing portion 6 (a boundary between the main body portion 10 and the wing portion 6).
  • a straight line connecting two points at which the width of the absorbent article 1 suddenly increases on both sides in the longitudinal direction of the wing portion 6 can be regarded as the root 61 of the wing portion 6.
  • the surface on the opposite side of the clothing side surface in the wing portion 6 is constituted by the top sheet 2.
  • Adhesive portions 7 are respectively provided on the clothing side surfaces of the main body portion 10 and the wing portion 6.
  • the width direction of the absorbent article 1 is the X direction
  • the longitudinal direction is the Y direction.
  • the planar direction of the absorbent article 1 is the XY direction.
  • the shape of the main body 10 is not particularly limited as long as the shape matches the shape of the female body and the underwear, such as a rectangle, an ellipse, and an hourglass.
  • the total length in the longitudinal direction of the outer shape of the main body 10 is preferably 100 to 500 mm, and more preferably 150 to 350 mm. Further, the total dimension in the width direction in the outer shape of the main body 10 is preferably 30 to 200 mm, and more preferably 40 to 180 mm.
  • the top sheet 2 moves the body fluid such as urine and menstrual blood discharged from the wearer to the absorber 4 in the main body 10. Moreover, in the main-body part 10, at least one part of the top sheet 2 has liquid permeability, and has many opening parts for permeating body fluid. On the other hand, in the wing portion 6, the top sheet 2 is suitable for the wearer to bend the wing portion 6, and has a suitable rigidity so as not to give the wearer a feeling of strangeness even after being attached to the underwear. 3 is applied to the wing part 6 together.
  • the top sheet 2 is preferably made from a resin film.
  • the resin film used as the top sheet 2 is made from a copolymer of olefin and other monomers such as acrylic acid ester and vinyl acetate, polyolefin, polyester, polypropylene, polyethylene, polyethylene terephthalate, polyamide, cellulose acetate and the like.
  • the resin film used as the top sheet 2 is preferably a copolymer of an olefin and another monomer, or a polyolefin because it is highly flexible and less irritating to the skin.
  • the basis weight of the top sheet 2 is preferably 1 g / m 2 or more and 40 g / m 2 or less, more preferably 10 g / m 2 or more and 35 g / m 2 or less.
  • the thickness of the resin film which comprises the top sheet 2 becomes like this. Preferably it is 0.01 mm or more and 0.4 mm or less, More preferably, it is 0.1 mm or more and 0.35 mm or less. When the thickness of the resin film constituting the top sheet 2 is less than 0.01 mm, the concealment property described later of the top sheet 2 may be too small, and the thickness of the resin film constituting the top sheet 2 is 0.
  • the apparent thickness of the top sheet 2 is larger than the thickness of the resin film constituting the top sheet 2. large.
  • the apparent thickness of the top sheet 2 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.1 mm or more and 0.5 mm or less.
  • the top sheet 2 has a concealing property so that the body fluid absorbed by the absorber 4 is not visible from the outside.
  • the concealability of the top sheet 2 is caused by mixing a filler such as titanium oxide into the resin.
  • the filler is titanium oxide
  • the content of titanium oxide is preferably 1% or more and 50% or less, more preferably 3% or more and 15% or less with respect to the weight of the resin film.
  • the effect of concealing the body fluid absorbed by the absorbent body 4 in the top sheet 2 may be too small. If the content of titanium oxide exceeds 50% with respect to the weight of the resin film, it may be difficult to form a sheet of the resin containing titanium oxide.
  • the top sheet 2 extends in the longitudinal direction, and first mountain folds 21 and valley folds alternately arranged in the width direction, and a second mountain extending in a direction intersecting the first mountain folds 21. And a folding portion 22.
  • an opening described later is further formed in the top sheet 2 in the region 12 where the absorber 4 of the main body 10 is provided.
  • a blood modifying agent layer described later is provided on the surface of the top sheet 2.
  • the excretion opening contact area 16 is preferably 50 to 200 mm in length in the longitudinal direction centered on the position of contact with the excretion opening of the body fluid of the wearer, more preferably 70 to 150 mm.
  • the region of the absorbent article 1 has a length in the width direction of preferably 10 to 80 mm, more preferably 20 to 50 mm.
  • FIG. 3 shows the first mountain fold portion 21 formed in the region 14 outside the both side surfaces 41 in the width direction of the absorbent body 4 in the top sheet 2 of the main body 10 and the top sheet 2 of the wing portion 6 (see FIG. 1).
  • FIG. 4 is a diagram for explaining a second mountain fold portion 22 and a valley fold portion 23.
  • the top sheet 2 extends in the longitudinal direction (Y direction) in the region 14 outside the side surfaces 41 in the width direction of the absorbent body 4 and the wing portion 6, and the width direction (X First mountain folds 21 and valley folds 23 that are alternately arranged in the direction).
  • the cross-sectional shape of the 1st mountain fold part 21 and the valley fold part 23 is a substantially U shape, for example.
  • the substantially U-shape includes a shape that becomes U-shaped when a modification such as rounding a corner or changing a straight line to a curve is applied.
  • the substantially U shape includes a V shape, an M shape, a trapezoid, and an ⁇ shape.
  • the second mountain fold portion 22 extends in a direction intersecting the first mountain fold portion 21 extending in the longitudinal direction (Y direction).
  • the angle formed between the direction in which the first mountain fold portion 21 extends and the direction in which the second mountain fold portion 22 extends is preferably 10 ° or more and 170 ° or less.
  • the cross-sectional shape of the second mountain fold 22 when the second mountain fold 22 is cut in a direction orthogonal to the direction in which the second mountain fold 22 extends is, for example, a substantially U shape.
  • the second mountain fold 22 may not be provided on the top sheet 2, but the first mountain fold 21 is not easily crushed by forming the second mountain fold 22. It is preferable to provide the folding portion 22 on the top sheet 2.
  • the number of first mountain folds 21 per 1 cm in the width direction is preferably 3 or more, and more preferably 5 or more.
  • the bottom of the valley folds 23 in the wings 6 comes into contact with a blood modifying agent layer described later in the excretory opening contact region 16. There is a case.
  • the length of the second mountain fold portion 22 in the longitudinal direction (Y direction) is preferably 0.3 mm or more and 5 mm or less, more preferably 0.5 mm or more and 3 mm or less.
  • the length in the longitudinal direction (Y direction) of the second mountain fold portion 22 is smaller than 0.3 mm, the effect of making the first mountain fold portion 21 difficult to collapse may not appear.
  • the length of the longitudinal direction (Y direction) of the 2nd mountain fold part 22 is larger than 5 mm, the below-mentioned blood modifier layer in the top sheet 2 in the wing part 6 and the excretory opening contact area 16 and The contact area between the two may not be too small.
  • the top sheet 2 does not include an opening part to be described later.
  • FIG. 4 shows the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 formed in the excretion opening contact area 16 in the top sheet 2 of the absorbent article 1 according to the embodiment of the present invention. It is a figure for demonstrating.
  • the top sheet 2 in the excretory opening contact area 16 is similar to the top sheet 2 in the outer region 14 on both side surfaces 41 in the width direction of the absorbent body 4 of the main body 10 and the wing 5.
  • a first mountain fold part 21, a second mountain fold part 22, and a valley fold part 23 are included.
  • the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 of the top sheet 2 in the excretory opening contact area 16 further add a blood modifying agent layer 24 described later on the skin side surface.
  • the first mountain fold portion 21 and the valley fold portion 23 of the top sheet 2 in the excretion opening contact area 16 further include an opening 25 on the side surface 26.
  • the first mountain fold portion 21 and the valley fold portion 23 of the top sheet 2 in the excretory opening contact area 16 have a plurality of openings 25 arranged in the longitudinal direction (Y direction) on both side surfaces 26 thereof.
  • the body fluid of the wearer discharged to the top sheet 2 in the excretory opening contact area 16 passes through the opening 25 and moves to the absorber 4.
  • emitted by the top sheet 2 gathers toward the bottom of the valley fold part 23 rapidly by the substantially U shape of the width direction (X direction) formed of the valley fold part 23.
  • the body fluid accumulated in the valley fold portion 23 also passes through the first mountain fold portion 21 and the opening 25 provided in the side surface 26 of the valley fold portion 23 and flows to the absorber 4. Therefore, the body fluid of the wearer is quickly absorbed by the absorbent body 4 through the openings 25 provided on the side surfaces 26 of the first mountain fold portion 21 and the valley fold portion 23. Further, the amount of body fluid remaining on the top sheet 2 can be reduced by the openings 25 provided on the side surfaces 26 of the first mountain fold portion 21 and the valley fold portion 23.
  • a blood modifying agent is applied to the skin side surface of the top sheet 2 in the excretory opening contact area 16, and the blood modifying agent layer 24 is provided on the skin contacting side surface of the top sheet 2.
  • the blood modifying agent layer 24 is within the range covered by the folded wings 6. Is preferably provided. Thereby, when the absorbent article 1 is packaged, the blood modifier layer 24 is protected by the folded wing portion 6.
  • the blood modifying agent layer 24 can suppress the body fluid of the wearer, in particular, the body fluid having a high viscosity (for example, menstrual blood having a high viscosity) remaining on the surface of the top sheet 2.
  • the blood modifying agent layer 24 may be provided in a region other than the excretion opening contacting area 16. However, it may not be provided.
  • the blood modifying agent layer 24 will be described in detail later.
  • the touch of the top sheet 2 is improved. .
  • the contact area between the wearer's skin and the top sheet 2 is reduced, the touch of the top sheet 2 is improved.
  • the first mountain fold portion is not easily crushed by providing the second mountain fold portion, the first mountain fold portion and the second mountain fold portion are formed on the top sheet 2 of the excretory opening contact area 16. It is preferable to provide a valley fold.
  • an opening is formed on the side surface of the top sheet 2 similarly to the excretion opening contact area 16.
  • the 1st mountain fold part 21, the valley fold part 23, and the 2nd mountain fold part 22 are provided.
  • the blood modifying agent layer 24 is not provided on the surface of the top sheet 2 in a region other than the excretory opening contact region 16 in the region 12 where the absorber 4 of the main body 10 is provided.
  • the blood modifying agent layer 24 may be provided on the surface of a part or all of the topsheet 2 in a region other than the excretory opening contact region 16 in the region 12 where the absorber 4 of the main body 10 is provided. Thereby, it can suppress that a wearer's bodily fluid which flowed out from the excretion opening
  • the top sheet 2 is preferably provided with a first mountain fold, a second mountain fold, and a valley fold 23.
  • the opening 25 is provided at least in the excretion opening contact area 16 of the top sheet 2, an opening is provided in a part or all of the area other than the excretion opening contact area 16 in the area 12 in which the absorber 4 is provided. 25 may not be provided. If the body fluid discharged from the wearer does not flow out from the excretion opening contact area 16 on the surface of the top sheet 2, it may not be necessary to form the opening 25 in a region other than the excretion opening contact area 16. It is. Moreover, you may provide the opening part 25 in a part of area
  • the body fluid that has flowed out from the region 12 where the absorber 4 of the main body 10 is provided is an opening provided in the region 14 outside the both edges 41 in the width direction of the absorber 4. Since it is absorbed into the absorbent body 4 through the body fluid, it is possible to further suppress the body fluid discharged from the wearer from leaking out from the edge of the absorbent article 1.
  • a material that does not transmit body fluid is used for the backsheet 3.
  • a hydrophobic nonwoven fabric, a water-impermeable plastic film such as polyethylene and polypropylene, or a laminate sheet of a nonwoven fabric and a water-impermeable plastic film is used as the back sheet 3.
  • a spunbond / meltblown / spunbond (SMS) fiber nonwoven fabric in which a melt-blown nonwoven fabric having high water resistance is sandwiched between strong spunbond nonwoven fabrics may be used as the back sheet 3.
  • SMS spunbond / meltblown / spunbond
  • the use of a breathable material that does not allow body fluid to pass through can be used to reduce stuffiness when worn.
  • the backsheet 3 is joined to the bottom of the valley fold 23 of the topsheet 2 using an adhesive such as a hot melt adhesive.
  • the absorber 4 absorbs and holds the body fluid. It is preferable that the absorber 4 is bulky, does not easily lose its shape, and has little chemical stimulation.
  • the absorbent body 4 a composite absorbent body made of fluffy pulp or air laid nonwoven fabric and a super absorbent polymer (SAP) is used as the absorbent body 4. This composite absorbent body may be covered with a liquid-permeable material such as a tissue.
  • the basis weight of absorbent fibers such as pulp in the composite absorbent is preferably 100 g / m 2 or more and 800 g / m 2 or less, and the mass ratio of the superabsorbent polymer in the composite absorbent is absorbent.
  • the fiber content is preferably 10% or more and 65% or less with 100%.
  • the basis weight of the liquid-permeable material such as a tissue covering the composite mixture is preferably 12 g / m 2 or more and 30 g / m 2 or less.
  • the air-laid nonwoven fabric of the above composite mixture for example, a nonwoven fabric obtained by thermally fusing pulp and synthetic fiber or a nonwoven fabric obtained by fixing pulp and synthetic fiber with a binder can be used.
  • the superabsorbent polymer of the composite absorbent has a three-dimensional network structure in which water-soluble polymers are appropriately crosslinked.
  • This absorbent polymer absorbs 30 to 60 times as much water as the volume of the absorbent polymer before absorbing water.
  • this absorbent polymer is essentially water insoluble.
  • the absorbent polymer for example, a starch-based, acrylic acid-based or amino acid-based particulate or fibrous polymer is used.
  • the shape and structure of the absorbent body 4 can be changed as necessary, the total amount of absorption of the absorbent body 4 needs to correspond to the design insertion amount and the desired application as the absorbent article 1. Further, the size and absorption capacity of the absorber 4 vary depending on the application.
  • the absorber 4 is bonded to the top sheet 2 using a hot melt adhesive. Thereby, it can suppress that the top sheet 2 peels from the absorber 4.
  • the wing portion 6 is provided in the absorbent article 1 in order to stably fix the absorbent article 1 to the underwear.
  • the absorbent article 1 can be stably fixed to the undergarment by bending the wing part 6 to the outer surface side of the undergarment and then sticking it to the crotch region of the undergarment via the adhesive part 7.
  • the main body portion 10 is also provided with an adhesive portion 7, which prevents the main body portion 10 from moving in the crotch region of the underwear.
  • the adhesive part 7 of the absorbent article 1 shown in FIG. 2 fixes the absorbent article 1 to the crotch region of the underwear.
  • a styrene polymer for example, a styrene polymer, a tackifier, or a plasticizer, which is a main component, is preferably used.
  • the styrenic polymer include styrene-ethylene-butylene-styrene block copolymers, styrene-butylene polymers, styrene-butylene-styrene block copolymers, and styrene-isobutylene-styrene copolymers. Only one of them may be used, or two or more polymer blends may be used. Of these, a styrene-ethylene-butylene-styrene block copolymer is preferred because of its good thermal stability.
  • tackifier and plasticizer those that are solid at room temperature can be preferably used.
  • the tackifier include C5 petroleum resins, C9 petroleum resins, dicyclopentadiene petroleum resins, and rosin petroleum resins.
  • Polyterpene resin, terpene phenol resin, etc., and examples of the plasticizer include monomer plasticizers such as trifresil phosphate, dibutyl phthalate and dioctyl phthalate, and polymer plasticizers such as vinyl polymers and polyesters. It is done.
  • the top sheet 2 and the absorbent body 4 have a compressed groove 8 that is formed by embossing and compressed in the thickness direction and extends from the top sheet 2 to the inside of the absorbent body 4.
  • the compressed groove 8 suppresses diffusion of body fluid discharged to the central portion of the absorbent article 1 (portion that contacts the wearer's body fluid excretion opening) in the width direction (X direction). Moreover, it can suppress that the top sheet 2 peels from the absorber 4 by this.
  • the compressed groove 8 surrounds the central portion of the absorbent article 1 and has a continuous substantially annular shape.
  • the pressing groove 8 surrounding the center part of the absorbent article 1 may be partially interrupted. That is, the pressing groove 8 may have a discontinuous substantially annular shape.
  • seal portions 9 are formed at the edge portions on both sides in the longitudinal direction of the main body portion 10 and the edge portions on the outer side in the width direction of the wing portions 6. The Thereby, the top sheet 2 can be prevented from being peeled off from the back sheet 3.
  • the blood modifying agent in the blood modifying agent layer 24 is about 0.00 to about 0.60 to about 0.60 IOB, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. Having a water solubility of 00 to about 0.00 to about 0.05 g.
  • IOB Inorganic Organic Balance
  • IOB is an index indicating a balance between hydrophilicity and lipophilicity.
  • Oda et al. IOB value calculated by inorganic value / organic value.
  • the IOB is about 0.00 to about 0.60, preferably about 0.00 to about 0.50, and preferably about 0.00 to about 0.40. More preferred is about 0 to about 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity with blood cells.
  • melting point means a peak top temperature of an endothermic peak when changing from a solid state to a liquid state when measured with a differential scanning calorimeter at a heating rate of 10 ° C./min.
  • the melting point can be measured, for example, using a DSC-60 type DSC measuring apparatus manufactured by Shimadzu Corporation.
  • the blood modifying agent may be liquid or solid at room temperature, as long as it has a melting point of about 45 ° C. or lower, that is, whether the melting point is about 25 ° C. or more, or less than about 25 ° C. Well, and can have a melting point of, for example, about ⁇ 5 ° C., about ⁇ 20 ° C., and the like. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.
  • the blood modifying agent has a lower melting point, but preferably has a low vapor pressure.
  • the blood pressure of the blood modifying agent is preferably about 0.00 to about 0.01 Pa, more preferably about 0.000 to about 0.001 Pa at 1 atmosphere and 25 ° C., and about 0 More preferably, it is from 0000 to about 0.0001 Pa.
  • the vapor pressure is preferably about 0.00 to about 0.01 Pa at 1 atmosphere and 40 ° C., and about 0.000 to More preferably, it is about 0.001 Pa, and more preferably about 0.0000 to about 0.0001 Pa. This is because if the vapor pressure is high, vaporization may occur during storage, and problems such as a decrease in the amount of blood modifying agent and odor when worn may occur.
  • the melting point of the blood modifying agent can be properly used according to the climate, the length of wearing time, and the like. For example, in an area where the average temperature is about 10 ° C. or less, even when the menstrual blood is excreted and then cooled by the ambient temperature by adopting a blood modifying agent having a melting point of about 10 ° C. or less. It is considered that the blood modifying agent can stably modify blood. Further, when the absorbent article is used for a long time, the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or lower. This is because the blood modifying agent is difficult to move even when it is worn for a long time, and is hardly affected by sweat, friction at the time of wearing, and the like.
  • the water solubility of 0.00-0.05 g was obtained by adding 0.05 g of sample to 100 g of deionized water at 25 ° C., leaving it to stand for 24 hours, and after 24 hours, gently stirring as necessary. Then, it can be measured by visually evaluating whether or not the sample is dissolved.
  • dissolution includes a case where the sample is completely dissolved in deionized water to form a uniform mixture and a case where the sample is completely emulsified.
  • “Complete” means that there is no lump of sample in deionized water.
  • top sheets coated with surfactants are well-suited to hydrophilic components (blood plasma, etc.) in blood, but rather leave blood on the top sheet. There is a tendency to work. Since the blood modifying agent has low water solubility, it is considered that blood can be quickly transferred to the absorbent body without remaining on the top sheet, unlike conventionally known surfactants.
  • solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.
  • a weight average molecular weight means the value of polystyrene conversion calculated
  • GPC measurement conditions include the following. Model: Hitachi High-Technologies Corporation High-Performance Liquid Chromatogram Lachrom Elite Column: SHODEX KF-801, KF-803 and KF-804 manufactured by Showa Denko K.K. Eluent: THF Flow rate: 1.0 mL / min Driving amount: 100 ⁇ L Detection: RI (differential refractometer)
  • the weight average molecular weight described in the Example of this specification is measured on the said conditions.
  • the blood modifying agent is preferably the following (i) to (iii), (I) hydrocarbons, (Ii) from (ii-1) a hydrocarbon moiety and (ii-2) a carbonyl group (—CO—) and an oxy group (—O—) inserted between the C—C single bonds of the hydrocarbon moiety.
  • the hydrocarbon moiety A compound having one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH), which replaces a hydrogen atom; As well as any combination thereof.
  • hydrocarbon means a compound composed of carbon and hydrogen, and is a chain hydrocarbon, for example, a paraffinic hydrocarbon (also referred to as an alkane, which does not include a double bond and a triple bond).
  • a paraffinic hydrocarbon also referred to as an alkane, which does not include a double bond and a triple bond.
  • Olefinic hydrocarbons including one double bond, also referred to as alkene
  • acetylenic hydrocarbons including one triple bond, also referred to as alkyne
  • hydrocarbons containing two or more bonds selected from the above and cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
  • the hydrocarbons are preferably chain hydrocarbons and alicyclic hydrocarbons, more preferably chain hydrocarbons, two paraffin hydrocarbons, olefin hydrocarbons, and two double bonds. More preferred are hydrocarbons (not including triple bonds), and more preferred are paraffinic hydrocarbons.
  • the chain hydrocarbon includes a straight chain hydrocarbon and a branched chain hydrocarbon.
  • each oxy group (—O—) is not adjacent. Therefore, the compounds (ii) and (iii) do not include compounds having a continuous oxy group (so-called peroxides).
  • At least one hydrogen atom in the hydrocarbon moiety is more than a hydroxyl group (-) than in a compound in which at least one hydrogen atom in the hydrocarbon moiety is substituted with a carboxyl group (-COOH).
  • Compounds substituted with OH) are preferred.
  • Table 1 since the carboxyl group binds to menstrual metals and the like, and the inorganic value increases significantly from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use. This is because the value of IOB exceeds about 0.60, and the affinity with blood cells may be reduced.
  • the blood modifying agent is more preferably the following (i ′) to (iii ′), (I ′) hydrocarbon, (Ii ′) (ii′-1) a hydrocarbon moiety and (ii′-2) a carbonyl bond (—CO—), an ester bond (—COO) inserted between the C—C single bonds of the hydrocarbon moiety.
  • the blood modifying agent preferably has about 1.8 or less carbonyl bonds (—CO—) and 2 or less ester bonds (—COO—) per 10 carbon atoms in the hydrocarbon moiety. About 1.5 or less carbonate bonds (—OCOO—), about 6 or less ether bonds (—O—), about 0.8 or less carboxyl groups (—COOH), and / or hydroxyl groups (—OH) ) In a compound having about 1.2 or less.
  • the blood modifying agent is more preferably the following (A) to (F), (A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain An ester with a compound having one carboxyl group for substituting a hydrogen atom in the hydrocarbon moiety, (B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain An ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon moiety, (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety
  • (A1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (A1)”)
  • a chain hydrocarbon tetraol such as an alkanetetraol, such as pentaerythritol
  • a chain hydrocarbon triol such as an alkanetriol, such as glycerin
  • a chain hydrocarbon diol such as an alkanediol, such as, for example, Glycol.
  • Examples of the compound (A2) having a chain hydrocarbon moiety and one carboxyl group that replaces the hydrogen atom of the chain hydrocarbon moiety include: , Compounds in which one hydrogen atom on a hydrocarbon is replaced by one carboxyl group (—COOH), for example, fatty acids.
  • Examples of the compound (A) include (a 1 ) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) an ester of a chain hydrocarbon triol and at least one fatty acid, and (a 3 ) Esters of chain hydrocarbon diols with at least one fatty acid.
  • ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid examples include the following formula (1): Tetraesters of pentaerythritol and fatty acids of the following formula (2): Triesters of pentaerythritol and fatty acids of the following formula (3): Diester of pentaerythritol and fatty acid of the following formula (4): And monoesters of pentaerythritol and fatty acids. (Wherein R 1 to R 4 are each a chain hydrocarbon)
  • the ester of pentaerythritol and fatty acid has the above-mentioned IOB, melting point and water solubility.
  • a saturated fatty acid for example, a C 2 to C 30 saturated fatty acid, for example, acetic acid (C 2 ) (C 2 represents the number of carbon atoms, R 1 C, Corresponding to the carbon number of R 2 C, R 3 C or R 4 C, the same shall apply), propanoic acid (C 3 ), butanoic acid (C 4 ) and isomers thereof such as 2-methylpropanoic acid (C 4 ), pentanoic acid (C 5) and isomers thereof such as 2-methylbutanoic acid (C 5), 2,2-dimethyl propanoic acid (C 5), hexanoic acid (C 6), heptanoic acid (C 7) Octanoic acid (C 8) and isomers thereof, e.g., 2-ethylhexanoic acid (C 8), nonanoic acid (C 9), decanoic acid (C 10), dodecano
  • the fatty acid can also be an unsaturated fatty acid.
  • unsaturated fatty acid include C 3 to C 20 unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C 4 ), myristoleic acid (C 14 ), palmitoleic acid (C 16 ), Oleic acid (C 18 ), elaidic acid (C 18 ), vaccenic acid (C 18 ), gadoleic acid (C 20 ), eicosenoic acid (C 20 ), etc., diunsaturated fatty acids such as linoleic acid (C 18 ), Triunsaturated fatty acids such as eicosadienoic acid (C 20 ), such as linolenic acid such as ⁇ -linolenic acid (C 18 ) and ⁇ -linolenic acid (C 18 ), pinolenic acid (C 18 ), eleostearic acid, For example, ⁇ -eleostearic acid (C 18
  • the ester of pentaerythritol and fatty acid is an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, considering the possibility of modification by oxidation or the like. preferable.
  • the ester of pentaerythritol and fatty acid is preferably a diester, triester or tetraester, more preferably a triester or tetraester, in order to reduce IOB and make it more hydrophobic. And tetraesters are more preferred.
  • the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and fatty acid that is, in the above formula (1), R 1 C, R 2 C, R 3 C and When the total number of carbon atoms in the R 4 C portion is 15, IOB is 0.60. Therefore, in the tetraester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbons is about 15 or more.
  • tetraester of pentaerythritol and fatty acid for example, pentaerythritol, hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), for example, 2-ethylhexanoic acid (C 8 ),
  • examples thereof include tetraesters with nonanoic acid (C 9 ), decanoic acid (C 10 ) and / or dodecanoic acid (C 12 ).
  • the total number of carbon atoms of the fatty acid constituting the triester of pentaerythritol and fatty acid that is, in the above formula (2), R 1 C, R 2 C and R 3 C moieties
  • the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 19 or more.
  • the total number of carbon atoms of the fatty acid constituting the diester of pentaerythritol and fatty acid that is, the total number of carbon atoms of the R 1 C and R 2 C moieties in the above formula (3) is In the case of 22, the IOB is 0.59. Therefore, in the diester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 22 or more.
  • the number of carbons of the fatty acid constituting the monoester of pentaerythritol and fatty acid that is, in the above formula (4), the IOB is 25 when the carbon number of the R 1 C portion is 25. 0.60. Therefore, in the monoester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the number of carbon atoms of the fatty acid is about 25 or more. In the above calculation, the influence of double bonds, triple bonds, iso branches, and tert branches is not taken into consideration.
  • esters of pentaerythritol and fatty acids examples include Unistar H-408BRS, H-2408BRS-22 (mixed product) and the like (manufactured by NOF Corporation).
  • ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid examples include the following formula (5): Triester of glycerin and fatty acid of the following formula (6): A diester of glycerin and a fatty acid, and the following formula (7): (Wherein R 5 to R 7 are each a chain hydrocarbon) Monoester of glycerin and fatty acid.
  • the ester of the glycerin and the fatty acid constituting the ester of the glycerin and the fatty acid, as long as the ester of glycerin and the fatty acid satisfies the requirements for the IOB, melting point and water solubility,
  • the fatty acids listed in “esters of (a 1 ) chain hydrocarbon tetraols and at least one fatty acid”, that is, saturated fatty acids and unsaturated fatty acids are exemplified and modified by oxidation or the like.
  • it is preferable to use an ester of glycerin and a fatty acid derived from a saturated fatty acid that is, an ester of glycerin and a saturated fatty acid.
  • ester of glycerin and fatty acid is preferably a diester or triester, and more preferably a triester, in order to reduce IOB and make it more hydrophobic.
  • the triester of glycerin and a fatty acid is also called a triglyceride.
  • triester of glycerin and octanoic acid C 8
  • triester of glycerin and decanoic acid C 10
  • glycerin and dodecanoic acid C 12
  • triesters of glycerin with 2 or 3 fatty acids and mixtures thereof.
  • Examples of the triesters of glycerin and two or more fatty acids include triesters of glycerin and octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin, octanoic acid (C 8 ), and decane.
  • Acid (C 10 ) and Dodecanoic acid (C 12 ) Triester, Glycerin, Octanoic acid (C 8 ), Decanoic acid (C 10 ), Dodecanoic acid (C 12 ), Tetradecanoic acid (C 14 ), Hexadecanoic acid Examples thereof include triesters with (C 16 ) and octadecanoic acid (C 18 ).
  • the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid that is, R 5 C in formula (5) in order to make the melting point about 45 ° C. or less.
  • R 6 C and R 7 C moieties preferably have a total carbon number of about 40 or less.
  • the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid that is, in the formula (5), R 5 C, R 6 C and R 7 C moieties
  • the IOB is 0.60. Therefore, in the triester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 12 or more.
  • the triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute a human body, and thus is preferable from the viewpoint of safety.
  • triesters of glycerin and fatty acid include tricoconut oil fatty acid glyceride, NA36, panacet 800, panacet 800B and panacet 810S, and tri C2L oil fatty acid glyceride and tri CL oil fatty acid glyceride (above, manufactured by NOF Corporation). ) And the like.
  • the diester of glycerin and fatty acid is also referred to as diglyceride.
  • diester of glycerin and decanoic acid (C 10 ) diester of glycerin and dodecanoic acid (C 12 ), glycerin and hexadecanoic acid (C 16 ) Examples include diesters, diesters of glycerin and two fatty acids, and mixtures thereof.
  • the total number of carbon atoms of the fatty acid constituting the diester of glycerin and fatty acid that is, the total number of carbon atoms of the R 5 C and R 6 C moieties in the formula (6) is 16.
  • the IOB is 0.58. Therefore, in the diester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 16 or more.
  • the monoester of glycerin and fatty acid is also referred to as monoglyceride, and examples thereof include glycerin icosanoic acid (C 20 ) monoester, glycerin docosanoic acid (C 22 ) monoester, and the like.
  • the monoester of glycerin and fatty acid the number of carbon atoms of the fatty acid constituting the monoester of glycerin and fatty acid, that is, when the carbon number of the R 5 C moiety in the formula (7) is 19, the IOB is 0.59. It becomes. Therefore, in the monoester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the fatty acid has about 19 or more carbon atoms.
  • ester of (a 3 ) chain hydrocarbon diol and at least one fatty acid examples include C 2 to C 6 chain hydrocarbon diols such as C 2 to C 6 glycols such as ethylene glycol, propylene glycol and butylene. Examples thereof include monoesters or diesters of glycol, pentylene glycol or hexylene glycol and a fatty acid.
  • ester of the chain hydrocarbon diol and at least one fatty acid for example, the following formula (8): R 8 COOC k H 2k OCOR 9 (8) (Wherein k is an integer from 2 to 6 and R 8 and R 9 are each a chain hydrocarbon) A diester of a C 2 -C 6 glycol with a fatty acid and the following formula (9): R 8 COOC k H 2k OH (9) (Wherein k is an integer from 2 to 6 and R 8 is a chain hydrocarbon) And monoesters of C 2 -C 6 glycols and fatty acids.
  • the fatty acid to be esterified (corresponding to R 8 COOH and R 9 COOH in formula (8) and formula (9)) is C 2 -C 6 glycol.
  • an ester of a fatty acid satisfying the above requirements for IOB, melting point and water solubility for example, “(a 1 ) ester of a chain hydrocarbon tetraol and at least one fatty acid”
  • the fatty acids listed in the above that is, saturated fatty acids and unsaturated fatty acids are mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.
  • the ester of a C 2 ⁇ C 6 glycols and fatty acid in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C 2 ⁇ C 6 glycols and fatty acid, Nachi Suwa, C 2 An ester of ⁇ C 6 glycol and saturated fatty acid is preferred.
  • the ester of C 2 -C 6 glycol and fatty acid is an ester of glycol and fatty acid derived from glycol having a large carbon number, for example, butylene glycol, in order to reduce IOB and make it more hydrophobic. It is preferably an ester of glycol and fatty acid derived from pentylene glycol or hexylene glycol.
  • ester of C 2 -C 6 glycol and fatty acid is preferably a diester in order to reduce IOB and make it more hydrophobic.
  • examples of commercially available esters of C 2 -C 6 glycol and fatty acid include Compol BL and Compol BS (manufactured by NOF Corporation).
  • Compound (B1) Compounds having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety are listed as “Compound (A)” as Compound (A1). For example, pentaerythritol, glycerin, and glycol.
  • Examples of the compound (B2) having a chain hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the chain hydrocarbon moiety include: , Compounds in which one hydrogen atom of a hydrocarbon is replaced by one hydroxyl group (—OH), such as aliphatic monohydric alcohols, for example saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols Is mentioned.
  • saturated aliphatic monohydric alcohol examples include C 1 to C 20 saturated aliphatic monohydric alcohols such as methyl alcohol (C 1 ) (C 1 represents the number of carbon atoms, the same shall apply hereinafter), ethyl alcohol ( C 2 ), propyl alcohol (C 3 ) and isomers thereof such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and isomers thereof such as sec-butyl alcohol (C 4 ) and tert-butyl alcohol (C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof such as 2-ethylhexyl alcohol (C 8 ), nonyl alcohol (C 9 ), decyl alcohol (C 10 ), dodecyl alcohol (C 12 ), tetradecyl al Cole (C 14 ), Hexadecyl alcohols
  • Examples of the unsaturated aliphatic monohydric alcohol include those obtained by substituting one of the C—C single bonds of the saturated aliphatic monohydric alcohol with a C ⁇ C double bond, such as oleyl alcohol. It is commercially available from Shin Nippon Rika Co., Ltd. under the names of the Jamaica Coal series and the Angelo All series.
  • Examples of the compound (B) include (b 1 ) ethers of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as monoether, diether, triether and tetraether, preferably diether, triether.
  • Ethers and tetraethers more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (b 2 ) chain hydrocarbon triols and at least one aliphatic monohydric alcohol, such as monoethers, diethers and triether, preferably diethers and triethers and more preferably tri-ether, and (b 3) a chain hydrocarbon diol and at least one aliphatic monohydric ether alcohols, for example, mono- and diethers and, Mashiku diethers.
  • ethers of the chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol include, for example, the following formulas (10) to (13): (In the formula, R 10 to R 13 are each a chain hydrocarbon.) And tetraethers, triethers, diethers and monoethers of pentaerythritol and aliphatic monohydric alcohols.
  • Examples of the ether of the chain hydrocarbon triol and at least one aliphatic monohydric alcohol include, for example, the following formulas (14) to (16): (Wherein R 14 to R 16 are each a chain hydrocarbon.) And triethers, diethers and monoethers of glycerin and aliphatic monohydric alcohols.
  • Examples of the ether of the chain hydrocarbon diol and at least one aliphatic monohydric alcohol include the following formula (17): R 17 OC n H 2n OR 18 (17) (Wherein n is an integer from 2 to 6 and R 17 and R 18 are each a chain hydrocarbon) A diether of a C 2 -C 6 glycol and an aliphatic monohydric alcohol, and the following formula (18): R 17 OC n H 2n OH (18) (Wherein n is an integer from 2 to 6 and R 17 is a chain hydrocarbon) And monoethers of C 2 -C 6 glycols and aliphatic monohydric alcohols.
  • the total number of carbon atoms of the aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (10)
  • IOB is 0.44. Therefore, in the tetraether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 4 or more, the IOB is about 0.00 to about 0.60. Fulfill.
  • the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (11)
  • IOB is 0.57. Therefore, in the above-mentioned triether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more, the IOB is about 0.00 to about 0.60. Fulfill.
  • the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of pentaerythritol and aliphatic monohydric alcohol that is, in the formula (12), R 10
  • the IOB is 0.60. Therefore, in the diether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 15 or more, the IOB satisfies the requirement of about 0.00 to about 0.60. .
  • the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (13), R 10
  • the IOB is 0.59. Therefore, in the monoether of pentaerythritol and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the aliphatic monohydric alcohol has about 22 or more carbon atoms.
  • the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of glycerin and aliphatic monohydric alcohol that is, in the formula (14), R
  • the IOB is 0.50. Therefore, in the above triether of glycerin and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 3 or more, the IOB satisfies the requirement of about 0.00 to about 0.60. .
  • the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of glycerin and aliphatic monohydric alcohol that is, in the formula (15), R 14 and R 15
  • the IOB is 0.58. Therefore, in the diether of glycerin and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more.
  • the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol that is, the carbon of R 14 moiety in the formula (16).
  • the IOB is 0.58. Therefore, in the monoether of glycerin and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the aliphatic monohydric alcohol has about 16 or more carbon atoms.
  • the IOB is about 0. Satisfy requirements of 00 to about 0.60.
  • Compound (B) can be produced by dehydrating condensation of compound (B1) and compound (B2) in the presence of an acid catalyst.
  • C1 Carboxylic acids, hydroxy acids, alkoxy acids or oxo acids (hereinafter referred to as “compounds”) containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups that replace the hydrogen atom of the chain hydrocarbon moiety.
  • C1) may be referred to as, for example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a chain hydrocarbon dicarboxylic acid, such as an alkanedicarboxylic acid, such as ethanedioic acid.
  • the compound (C1) includes a chain hydrocarbon hydroxy acid having 2 to 4 carboxyl groups, for example, a chain chain having 2 to 4 carboxyl groups such as malic acid, tartaric acid, citric acid, isocitric acid and the like. Hydrocarbon alkoxy acids such as O-acetylcitric acid and chain hydrocarbon oxoacids having 2 to 4 carboxyl groups are included.
  • C2 Examples of the compound having a chain hydrocarbon moiety and one hydroxyl group substituting a hydrogen atom of the chain hydrocarbon moiety include those listed in the section of “Compound (B)”, for example, An aliphatic monohydric alcohol is mentioned.
  • Examples of the compound (C) include (c 1 ) an ester of a linear hydrocarbon tetracarboxylic acid having 4 carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid and at least one aliphatic monohydric alcohol, for example, Monoesters, diesters, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and tetraesters, and even more preferably tetraesters, (c 2 ) a chain having three carboxyl groups Esters of hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxo acids with at least one aliphatic monohydric alcohol, such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters Ester, and (c 3) a chain hydrocarbon dicarboxylic acids having two carboxyl groups, hydroxy acids, esters of alk
  • compound (D) a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—)
  • compound (D) include (d 1 ) aliphatic Examples include ethers of monohydric alcohols and aliphatic monohydric alcohols, (d 2 ) dialkyl ketones, (d 3 ) esters of fatty acids and aliphatic monohydric alcohols, and (d 4 ) dialkyl carbonates.
  • the ether satisfies the requirements of the IOB, melting point and water solubility.
  • the aliphatic monohydric alcohols listed in the section of “Compound (B)”.
  • the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether that is, the carbon number of R 19 and R 20 in the above formula (19). Since the IOB is 0.50 when the sum of the two is 2, the IOB requirement is satisfied if the total number of carbon atoms is about 2 or more. However, when the total number of carbon atoms is about 6, the water solubility is as high as about 2 g, which is problematic from the viewpoint of vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total number of carbon atoms is preferably about 8 or more.
  • dialkylketone As the dialkyl ketone, the following formula (20): R 21 COR 22 (20) (Wherein R 21 and R 22 are each an alkyl group) The compound which has is mentioned.
  • the total number of carbon atoms is preferably about 8 or more.
  • the carbon number is preferably about 10 or more, and more preferably about 12 or more.
  • the melting point is about ⁇ 50 ° C.
  • the vapor pressure is about 230 Pa at 20 ° C.
  • the dialkyl ketone can be obtained by a known method, for example, by oxidizing a secondary alcohol with chromic acid or the like.
  • ester of the fatty acid and the aliphatic monohydric alcohol include the following formula (21): R 23 COOR 24 (21) (Wherein R 23 and R 24 are each a chain hydrocarbon) The compound which has is mentioned.
  • Examples of the fatty acid constituting the ester are listed in “(a 1 ) ester of chain hydrocarbon tetraol and at least one fatty acid”.
  • Fatty acids that is, saturated fatty acids or unsaturated fatty acids can be mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.
  • Examples of the aliphatic monohydric alcohol constituting the ester include the aliphatic monohydric alcohols listed in the section “Compound (B)”.
  • the total number of carbon atoms of the fatty acid and the aliphatic monohydric alcohol is 5
  • the above IOB requirement is satisfied when the total number of carbon atoms in the R 23 C and R 24 portions is about 5 or more.
  • the total number of carbon atoms is preferably about 12 or more. If the total number of carbon atoms is about 11 or more, the water solubility can satisfy the requirement of about 0.00 to about 0.05 g.
  • ester of the fatty acid and the aliphatic monohydric alcohol examples include, for example, an ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 ).
  • ester of the fatty acid and the aliphatic monohydric alcohol examples include, for example, an ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 ).
  • Examples of commercially available esters of fatty acids and aliphatic monohydric alcohols examples include Electol WE20 and Electol WE40 (manufactured by NOF Corporation).
  • the dialkyl carbonate since the IOB is 0.57 when the total number of carbon atoms of R 25 and R 26 is 6, if the total number of carbon atoms of R 25 and R 26 is about 6 or more, Satisfy requirements. In consideration of water solubility, the total number of carbon atoms of R 25 and R 26 is preferably about 7 or more, and more preferably about 9 or more.
  • the dialkyl carbonate can be synthesized by a reaction between phosgene and an alcohol, a reaction between a chlorinated formate and an alcohol or an alcoholate, and a reaction between silver carbonate and an alkyl iodide.
  • Examples of the polyoxy C 2 -C 6 alkylene glycol, or an ester or ether thereof include (e 1 ) polyoxy C 2 -C 6 alkylene glycol, (e 2 ) polyoxy C An ester of 2 to C 6 alkylene glycol and at least one fatty acid, (e 3 ) an ether of polyoxy C 2 to C 6 alkylene glycol and at least one aliphatic monohydric alcohol, (e 4 ) polyoxy C 2 to C 6 Esters of alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid, and (e 5 ) polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetra All, chain hydrocarbon triols, or ethers with chain hydrocarbon diols That.
  • the oxy C 2 -C 6 alkylene skeleton is preferably an oxypropylene skeleton, an oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton from the viewpoint of lowering the IOB of the polyoxy C 2 -C 6 alkylene glycol.
  • An oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton is more preferable.
  • the polyoxy C 2 -C 6 alkylene glycol is represented by the following formula (23): HO- (C m H 2m O) n -H (23) (Where m is an integer from 2 to 6) Can be represented by:
  • the homopolymer of formula (23) may include a homopolymer of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. From the above, in formula (23), m is about 3 to about 6, more preferably about 4 to about 6, and n is 2 or more.
  • the value of n is such that the poly C 2 -C 6 alkylene glycol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. A value having a water solubility of about 0.00 to about 0.05 g.
  • the weight average molecular weight of the polyoxy C 2 -C 6 alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and more preferably It is in the range of about 250 to about 5,000.
  • the weight average molecular weight of poly C 3 alkylene glycol, ie, polypropylene glycol is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8 , And more preferably in the range of about 4,000 to about 5,000. This is because, when the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirement, and the higher the weight average molecular weight, the more the absorber transfer speed and the whiteness of the top sheet tend to be improved.
  • ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid examples include the OH terminal of the polyoxy C 2 -C 6 alkylene glycol described in the section “(e 1 ) polyoxy C 2 -C 6 alkylene glycol”. One or both of them are esterified with a fatty acid, that is, monoesters and diesters.
  • Examples of the fatty acid to be esterified in the ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid are listed in “Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”.
  • Fatty acids that is, saturated fatty acids or unsaturated fatty acids, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.
  • Examples of commercially available esters of the above polyoxy C 2 -C 6 alkylene glycol and fatty acid include Wilbright cp9 (manufactured by NOF Corporation).
  • the aliphatic monohydric alcohol to be etherified includes, for example, the aliphatic enumerated in the section of “Compound (B)” A monohydric alcohol is mentioned.
  • Esters of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid are commercially available, and chain hydrocarbon tetracarboxylic acid. It can be produced by polycondensing a C 2 -C 6 alkylene glycol to an acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid under known conditions.
  • chain hydrocarbon tetraol, chain hydrocarbon triol, and chain hydrocarbon diol to be etherified include those described in the section of “Compound (A)”, for example, pentaerythritol, glycerin, and glycol. Is mentioned.
  • Examples of commercially available ethers of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol include, for example, Unilube (trademark) 5TP-300KB, and And Uniol (trademark) TG-3000 and TG-4000 (manufactured by NOF Corporation).
  • Unilube (trademark) 5TP-300KB is a compound obtained by polycondensation of 65 mol of propylene glycol and 5 mol of ethylene glycol to 1 mol of pentaerythritol, its IOB is 0.39, and its melting point is less than 45 ° C. Yes, and the water solubility was less than 0.05 g.
  • Uniol TM TG-3000 is a compound obtained by polycondensation of 50 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.42, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 3,000.
  • Uniol TM TG-4000 is a compound obtained by polycondensation of 70 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.40, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 4,000.
  • the ether of the polyoxy C 2 -C 6 alkylene glycol and the chain hydrocarbon tetraol, the chain hydrocarbon triol, or the chain hydrocarbon diol is also a chain hydrocarbon tetraol, a chain hydrocarbon triol, or It can be produced by adding C 2 -C 6 alkylene oxide to a chain hydrocarbon diol under known conditions.
  • the chain hydrocarbon Since the chain hydrocarbon has an inorganic value of 0, the IOB is 0.00 and the water solubility is approximately 0 g. Therefore, if the melting point is about 45 ° C. or less, the blood It can be included in the modifier.
  • the chain hydrocarbon include (f 1 ) chain alkanes such as straight chain alkanes and branched chain alkanes. For example, in the case of straight chain alkanes, the melting point is about 45 ° C. or less. In general, those having 22 or less carbon atoms are included. Moreover, when the vapor pressure is taken into consideration, those having 13 or more carbon atoms are generally included.
  • the melting point may be lower at the same number of carbons than that of a straight chain alkane. Therefore, those having 22 or more carbon atoms may be included.
  • a commercial item of the above-mentioned hydrocarbon for example, Pearl Ream 6 (NOF Corporation) can be mentioned.
  • the above-mentioned blood modifying agent is considered in detail together with the examples, but it has been found that it has at least an action of lowering blood viscosity and surface tension.
  • menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall. Cheap. Therefore, menstrual blood to be absorbed by the absorbent article tends to have a high viscosity, and when the top sheet is a nonwoven fabric or a woven fabric, the menstrual blood easily clogs between the fibers, and the wearer feels sticky. Almost, and menstrual blood diffuses on the surface of the topsheet, making it easier to leak.
  • a blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily enters between blood cells, so that it stabilizes the blood cells and makes it difficult to form a monetary structure in the blood cells. It is considered possible. It is considered that the above-mentioned modifying agent stabilizes blood cells and makes it difficult to form a monetary structure on the blood cells, so that the absorbent body can easily absorb menstrual blood.
  • the blood modifying agent having a high affinity for red blood cells protects the red blood cell membrane, so that the red blood cells are hardly destroyed.
  • FIG. 5 is a view for explaining the absorbent article 1 in which the wing portion 6 is folded for packaging.
  • the pair of wing parts 6 are folded inward in the width direction as shown in FIG.
  • the adhesive part 7 is covered with a release sheet 33.
  • the peeling sheet 33 will not be specifically limited if it is a sheet
  • a release agent applied to a substrate can be used.
  • the substrate on which the release agent is applied include films such as polypropylene, low density polyethylene, and polyvinyl alcohol, non-woven fabric, and paper.
  • the release agent include silicone, fluorine, and isocyanate.
  • the absorbent article 1 in which the wing portion 6 is folded is disposed on the packaging material 31.
  • the packaging material 31 is made of, for example, a resin film and a nonwoven fabric.
  • a fastening tape 32 is provided at one end in the longitudinal direction of the packaging material 31.
  • the absorbent article 1 arranged on the packaging material 31 is folded together with the packaging material 31 in the longitudinal direction (Y direction) along the BB line and the CC line. Then, the fastening tape 32 is used to maintain the folded state of the absorbent article 1.
  • the both sides 31a of the width direction of the packaging material 31 folded together with the absorbent article 1 are joined by heat embossing. Thereby, the package 30 shown in FIG. 6 including the absorbent article 1 is produced.
  • FIG. 6 is a perspective view of the packaged product 30 including the absorbent article.
  • FIG. 7 is a schematic cross-sectional view showing a cross section along line DD of FIG.
  • the top sheet 2 in the wing part 6 when the wing part 6 is folded contacts the top sheet 2 in the excretory opening contact area 16 (see FIGS. 1 and 2). Since the blood modifying agent layer 24 is formed on the top sheet 2 in the excretory opening contact area 16, the top sheet 2 in the wing portion 6 comes into contact with the blood modifying agent layer 24. However, the contact area between the top sheet 2 and the blood modifying agent layer 24 in the wing portion 6 is reduced by the first mountain fold portion 21 and / or the second mountain fold portion 22. Moreover, the opening part is not formed in the top sheet 2 in the wing part 6.
  • the blood modifier of the blood modifier layer 24 osmose permeates the wing part 6, and the joint force between the top sheet 2 and the back sheet 3 in the wing part 6 weakens.
  • the blood modifying agent in the blood modifying agent layer 24 formed on the top sheet 2 in the excretory opening contact region 16 is transferred to the top sheet 2 in the wing portion 6 by transferring the blood modifying agent in the blood modifying agent layer 24. It can suppress that the quantity of decreases.
  • the seal portion 9 As shown in FIG. 7, by forming the seal portion 9 at the edge portion on the outer side in the width direction of the wing portion 6 provided with the first mountain fold portion 21 and / or the second mountain fold portion 22, The edge 62 (see FIGS. 1 and 2) of the wing portion 6 can be separated from the top sheet 2 of the excretory opening contact area 16 where the blood modifying agent layer is formed. As a result, the blood modifying agent in the blood modifying agent layer 24 penetrates between the top sheet 2 and the back sheet 3 at the end 62 of the wing part 2, and the gap between the top sheet 2 and the back sheet 3 in the wing part 2. It can suppress that the joining force of is weakened.
  • the top sheet 2 and the blood modifying agent layer in the wing portion 6 are provided.
  • the contact area with 24 is further reduced. Thereby, it can further suppress that the blood modifying agent of the blood modifying agent layer 24 penetrates into the wing part 6 and the bonding force between the top sheet 2 and the back sheet 3 in the wing part 6 is weakened.
  • the blood modifying agent in the blood modifying agent layer 24 formed on the top sheet 2 in the excretory opening contact region 16 is transferred to the top sheet 2 in the wing portion 6 by transferring the blood modifying agent in the blood modifying agent layer 24. It can suppress that the quantity of decreases.
  • FIG. 8 is a diagram for explaining the absorbent article manufacturing apparatus 100 used in the method for manufacturing the absorbent article 1 according to one embodiment of the present invention.
  • the manufacturing method of the absorbent article 1 includes a step of forming an absorbent body, a step of preparing a sheet for a top sheet, a step of forming a compressed groove in a laminate, a step of preparing a sheet for a back sheet, and a continuous body of absorbent articles. And a step of applying a blood modifying agent to the absorbent article.
  • the top sheet used in the step of preparing the top sheet includes a step of preparing a resin film sheet, a step of forming a recess in the resin film sheet, and a step of gear stretching on the resin film sheet. It is manufactured by the manufacturing method of the sheet.
  • the absorber 128 is formed on the belt 110.
  • the pulverized pulp 122 is supplied to the pattern drum 120 from a pulverized pulp supply device (not shown).
  • a recess 124 is formed on the outer periphery of the pattern drum 120 as a mold for filling pulverized pulp.
  • the inside of the pattern drum 120 is sucked 126, and the pulverized pulp 122 supplied to the pattern drum 120 is sucked into the recess 124 and compressed.
  • the pulp 122 is shape
  • the absorber 128 is placed on the belt.
  • the top sheet 216 manufactured by the top sheet manufacturing method described later is disposed on the absorber 128 and the top sheet 216 is bonded to the absorber 128. .
  • the embossing device 130 is used to form the compressed groove in the laminate 262 of the top sheet 216 and the absorbent body 128.
  • the laminate 262 passes between the upper roll 131 and the lower roll 132 of the embossing apparatus 130.
  • a convex portion (not shown) having a shape corresponding to the compressed groove 8 of the absorbent article 1 shown in FIG. 1 is provided on the outer peripheral surface of the upper roll 131.
  • the lower roll 132 is a plain roll having a smooth outer peripheral surface.
  • the backsheet sheet 142 supplied from the backsheet sheet roll 140 is coated with an adhesive using a coating device (not shown), and then laminated with a compressed groove formed.
  • a continuous body 144 of absorbent articles is formed by overlapping and adhering to the surface of the body 134 opposite to the top sheet side.
  • the absorbent article is manufactured by cutting the absorbent article continuous body 144 into the shape of the absorbent article using the cutter 150.
  • the above-described blood modifying agent 161 is applied to the central region of the absorbent article using the modifier coating spray 160, and the excretion of the top sheet is performed.
  • a blood modifying agent layer is formed on the surface of the contact area.
  • the blood modifying agent is applied after the step of cutting the continuous article of the absorbent article, the blood modifying agent may be applied in the manufacturing process of the sheet for top sheet described later.
  • the blood downstream of the manufacturing process of the absorbent article for example, immediately before packaging the absorbent article It is preferable to apply the modifier to the absorbent article.
  • the manufacturing method of the absorbent article 1 includes, in addition, a step of forming an adhesive portion on the continuous body 144 of the absorbent article, a step of forming a seal portion on the continuous body 144 of the absorbent article, and the like. Moreover, the manufactured absorbent article 1 is packaged using the packaging material described above.
  • the resin film sheet 212 supplied from the roll 210 of the resin film sheet is supplied to the recess forming roll 220.
  • the resin film sheet 212 is passed through the recess forming roll 220 to produce the resin film sheet 214 (see FIG. 10) in which the recesses 2141 are formed.
  • the recess forming roll 220 includes a knurled roll 221 and a preheating roll 222 having a smooth surface.
  • FIGS. 9A and 9B are diagrams illustrating an example of the knurled roll 221.
  • FIG. 9A is a diagram illustrating the entire knurled roll 221
  • FIG. 9B is an enlarged view of a portion 223 having irregularities on the outer peripheral surface of the knurled roll 221.
  • FIG. 9C is a diagram showing an example of the preheating roll 222 having a smooth surface.
  • grid-like convex portions 224 are provided on the surface 223 of the knurled roll 221.
  • a diamond-shaped recess 225 is formed on the surface of the knurled roll 221.
  • the shape of the recessed part 225 of the knurled roll 221 is not limited to a rhombus, and may be a square, a rectangle, a parallelogram, a trapezoid, a triangle, a hexagon, or the like.
  • the interval between the center lines of the projections 224 arranged in parallel in the grid-like projections 224, that is, the pitch of the grid-like projections 224 is preferably 0.2 mm or more and 10 mm or less, more preferably 0.4 mm or more and 2 mm. It is as follows. When the pitch of the grid-like convex portions 224 is less than 0.2 mm or larger than 10 mm, the concave portions may not be formed in the resin film. Further, the width of the grid-like convex portion 224 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.03 mm or more and 0.1 or less.
  • the length of one side of the rhombic recess 225 is preferably 0.1 mm or more and 5 mm or less, more preferably 0.2 mm or more and 1 mm or less.
  • the width of the grid-like convex portion 224 is less than 0.01 mm or larger than 1 mm, or when the length of one side of the rhombic concave portion 225 is less than 0.1 mm or larger than 5 mm, the concave portion may not be formed in the resin film. .
  • the preheating roll 222 having a smooth surface is maintained at a temperature of 70 ° C. or higher and 100 ° C. or lower, and heats the supplied resin film sheet 212. Thereby, the resin film sheet 212 becomes soft and easy to mold.
  • the resin film sheet 212 When the resin film sheet 212 passes between the knurled roll 221 and the roll 222 having a smooth surface, the resin film sheet 212 receives a strong pressure in the thickness direction at a portion in contact with the grid-like convex portion 224. Thereby, as shown in FIG. 10, fine concave portions 2141 are formed in the resin film sheet 214.
  • the recesses 2141 formed in the resin film sheet 212 are smaller than those shown in FIG. 10, and the number of recesses 2141 per unit area is much larger than that shown in FIG.
  • the recess 2141 is formed only in a range 2143 corresponding to the region 12 (see FIG. 1) where the absorber 4 of the main body 10 is provided in the resin film sheet 214.
  • the range corresponding to the absorbent article 1 in the resin film sheet 214 is a range indicated by a dotted line 2142.
  • the resin film sheet 214 having a recess is passed through the stretching gear roll 230 shown in FIG. 8, whereby the first mountain fold portion, the second mountain fold portion of the top sheet 2, A valley fold is formed in the resin film sheet 214.
  • Reference numeral 216 denotes a resin film sheet in which a first mountain fold, a second mountain fold, and a valley fold are formed.
  • the stretching gear roll 230 includes an upper roll 231 and a lower roll 232.
  • 11A is a view for explaining the upper roll 231 of the stretched gear roll 230
  • FIG. 11B is a view for explaining the gear teeth 233 arranged on the outer peripheral surface of the upper roll 231.
  • FIG. 11C is a cross-sectional view taken along the line EE of FIG.
  • the gear teeth 233 extend discontinuously in the circumferential direction of the upper roll 231. That is, the gear teeth 233 extending in the circumferential direction of the upper roll 231 are interrupted at a plurality of locations on the way.
  • a second mountain fold is formed in the resin film sheet 214 by the portion 234 where the gear teeth 233 are interrupted.
  • the width of the gear teeth 233 is, for example, 0.3 mm or more and 0.5 mm or less, and the distance between the centers of the adjacent gear teeth 233 is, for example, 1.0 mm or more and 1.2 mm or less.
  • FIG. 12A is a view for explaining the lower roll 232 of the stretched gear roll 230
  • FIG. 12B is a view for explaining the gear teeth 235 arranged on the outer peripheral surface of the lower roll 232
  • FIG. 12C is a cross-sectional view taken along line FF in FIG.
  • the gear teeth 235 extend in the circumferential direction of the lower roll 232.
  • the lower roll 232 is not interrupted at a plurality of locations on the way like the upper roll 231.
  • the width of the gear teeth 235 is, for example, equal to the width of the gear teeth 233 of the upper roll 231, and the distance between the centers of the adjacent gear teeth 235 is, for example, equal to the distance between the centers of the gear teeth 233 of the upper roll 231.
  • the length in the radial direction of the upper roll 231 at the portion where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are meshed, that is, the biting depth is, for example, 1.25 mm.
  • the gap between the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 when the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are meshed is, for example, 0.25 mm or more 0.45 mm or less.
  • the resin film sheet 214 passes through the stretched gear roll 230, the resin film 214 is bent into a substantially wave shape, and the first mountain fold portion 21 and the second mountain fold of the top sheet 2 are formed on the resin film 214. A portion 22 and a valley fold portion 23 are formed. Moreover, the opening part 25 (refer FIG. 4) of the top sheet 2 is further formed in the area
  • the resin film sheet 214 is greatly stretched at a portion 236 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged.
  • the portion where the concave portion 2141 (see FIG. 10) is formed in the concave portion forming step described above is a portion where the resin film sheet 214 is thin and further scratched by the lattice-shaped convex portions 224 of the knurled roll 221. Therefore, the strength is weak, and the recess 2141 of the resin film sheet 214 is broken when it is stretched.
  • the recess 2141 of the resin film sheet 214 is torn, the torn portion of the resin film sheet 214 spreads, and an opening is formed in the torn portion of the resin film sheet 214. It is formed.
  • the resin film sheet 214 is not stretched so much at the portions 237 and 238 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are not engaged. For this reason, even if the resin film sheet 214 passes through the stretched gear roll 230 in the portions 237 and 238 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are not engaged with each other in the resin film sheet 241, The recess 2141 formed in the recess forming process is not torn and does not become an opening.
  • the absorbent article 1 can be modified as follows. (1) If the contact area between the blood modifying agent layer 24 provided on the top sheet 2 of the main body part 10 and the top sheet 2 of the wing part 6 can be reduced, the top sheet of the wing part 6 is formed.
  • the protrusion is not limited to the first mountain fold and the second mountain fold.
  • a mountain fold portion extending in the width direction (X direction) may be provided on the top sheet of the wing portion 6.
  • a protrusion having a shape such as a cylinder, a prism, or a hemisphere may be provided on the top sheet of the wing portion 6.
  • the side sheets 18A may be arranged on both sides of the top sheet 2A.
  • the wing part 6 includes a side seat 18A and a back seat.
  • the side sheet 18A is a resin film, and the side sheet 18A does not have an opening in the wing portion 6 and includes protrusions such as the first mountain fold portion 21 and the second mountain fold portion. .
  • the side sheet 18A which comprises the wing part 6 peels from a back sheet
  • the side sheet 18A is provided with a first mountain fold part 21, a second mountain fold part 22, and a valley fold part 23, and the top sheet 2A has a first mountain fold part 21 and a second mountain fold part 22.
  • the valley fold 23 may not be provided.
  • the blood modifying agent applied to the top sheet 2 of the main body part 10 can permeate the wing part 6, thereby preventing the side sheet 18 ⁇ / b> A constituting the wing part 6 from peeling from the back sheet.
  • the non-woven fabric used for the top sheet 2A may be a natural fiber or a chemical fiber.
  • natural fibers used for the top sheet 2A include cellulose such as pulverized pulp and cotton.
  • Chemical fibers used for the top sheet 2A include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fibers, and thermoplastic hydrophobic chemical fibers subjected to hydrophilic treatment. Can be mentioned.
  • thermoplastic hydrophobic chemical fibers used for the top sheet 2A include single fibers such as polyethylene (PE), polypropylene (PP), and polyethylene terephthalate (PET), fibers formed by graft polymerization of polyethylene and polypropylene, and a core-sheath structure.
  • PE polyethylene
  • PP polypropylene
  • PET polyethylene terephthalate
  • a composite fiber is mentioned.
  • the protrusion formed on the top sheet 2 in the discharge port facing area 16 is not limited to the first protrusion.
  • a ridge that extends in the longitudinal direction (Y direction) or the width direction (X direction) in a wavy form may be provided on the top sheet of the outlet facing region 16 where the blood modifying agent layer is formed. .
  • a protrusion having a shape such as a cylinder, a prism, or a hemisphere may be provided on the top sheet of the discharge port facing region 16 where the blood modifying agent layer is formed.
  • a protrusion having a shape such as a cylinder, a prism, or a hemisphere.
  • the blood modifying agent in the blood modifying agent layer is transferred to the top sheet of the wing part, and the amount of blood modifying agent in the blood modifying agent layer formed on the top sheet in the discharge port facing region is reduced. Can be suppressed.
  • the layer formed in at least the excretion contact area in contact with the wearer's excretion opening on the skin side surface of the top sheet is a composition application layer coated with a predetermined composition
  • the blood modifying agent It is not limited to layers.
  • the blood modifying agent since the blood modifying agent has a mechanism for lowering the viscosity and surface tension of blood, the body fluid moves to the absorber 4 without remaining in the top sheet 2 by the blood modifying agent layer 24, and the absorber. 4 can be absorbed.
  • the following examples confirmed that the blood modifying agent has a mechanism for lowering blood viscosity and surface tension. This confirmation was performed using a non-woven fabric in which a body fluid is likely to remain as compared with a resin film.
  • the sanitary napkin includes a top sheet formed from an air-through nonwoven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent, and an air-through nonwoven fabric (composite made of polyester and polyethylene terephthalate).
  • an air-through nonwoven fabric composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2
  • an air-through nonwoven fabric composite made of polyester and polyethylene terephthalate
  • Second sheet formed from fibers, basis weight: 30 g / m 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the center), acrylic superabsorbent polymer (basis weight: 15 g / m 2 ) And an absorbent body containing a tissue as a core wrap, a side sheet treated with a water repellent, and a back sheet made of a polyethylene film.
  • Tri-C2L oil fatty acid glyceride manufactured by NOF Corporation C 8 fatty acid: C 10 fatty acid: C 12 fatty acid containing approximately 37: 7: 56 weight ratio, glycerol and fatty acid triester, Weight average molecular weight: about 570
  • fatty acids manufactured by NOF Corporation C 8 fatty to C 10 are contained in approximately 85:15 weight ratio of triesters of glycerol with fatty acids, the weight average molecular weight: about 480 ⁇ Panasate 800, manufactured by NOF Corporation All fatty acids are octanoic acid (C 8 ), triester of glycerin and fatty acid, weight average molecular weight: about 470
  • Panaceate 800B manufactured by NOF Corporation All fatty acids are 2-ethylhexanoic acid (C 8 ), triester of glycerin and fatty acid, weight average molecular weight: about 470 ⁇ NA36, manufactured by NOF Corporation C 16 fatty acid: fatty acid C 18: (including both saturated and unsaturated fatty acids) fatty acids to C 20 is approximately 5: contained in a weight ratio of 3: 92 Triester of glycerin and fatty acid, weight average molecular weight: about 880
  • C 8 fatty C 10: fatty acid
  • C 12 fatty acid
  • C 14 (including both saturated and unsaturated fatty acids)
  • C 16 is approximately 4 : Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670 -Caprylic acid diglyceride, manufactured by NOF Corporation
  • Fatty acid is octanoic acid, diester of glycerin and fatty acid, weight average molecular weight: 340
  • Uniol PB1000R polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1000 [(E 2 ) ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid] -Wilbright cp9, manufactured by NOF Co., Ltd.
  • Uniol TG-3000 manufactured by NOF Corporation Polyglycol glycol glyceryl ether, about 16 repeating units, weight average molecular weight: about 3,000 ⁇ Uniol TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000
  • [Other materials] -NA50 manufactured by NOF Corporation Hydrogen added to NA36 to reduce the ratio of double bonds derived from the unsaturated fatty acid as a raw material Triester of glycerin and fatty acid, weight average molecular weight: about 880 -(Caprylic acid / Capric acid) monoglyceride, NOF Corporation Octanoic acid (C 8 ) and Decanoic acid (C 10 ) in a weight ratio of approximately 85:15, monoester of glycerin and fatty acid, Weight average molecular weight: about 220 -Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan
  • PEG 1500 manufactured by NOF Corporation, polyethylene glycol, weight average molecular weight: about 1,500 to about 1,600 Nonionic S-6, polyoxyethylene monostearate manufactured by NOF Corporation, about 7 repeating units, weight average molecular weight: about 880 -Wilbright s753, NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960
  • the IOB, melting point and water solubility of the above sample are shown in Table 2 below.
  • the water solubility was measured according to the method described above, but 20.0 g was added to 100 g of demineralized water, and the sample dissolved after 24 hours was evaluated as “20 g ⁇ ”, and the sample was dissolved in 100 g of demineralized water. , 0.05 g dissolved, but 1.00 g not dissolved sample was evaluated as 0.05 to 1.00 g.
  • “ ⁇ 45” means that the melting point is less than 45 ° C.
  • the skin contact surface of the top sheet of the sanitary napkin was coated with the blood modifying agent described above.
  • Each blood modifying agent is heated as it is if the blood modifying agent is liquid at room temperature, and if the blood modifying agent is solid at room temperature, it is heated to melting point + 20 ° C., and then control seam HMA gun
  • Each blood modifying agent was atomized and applied to the entire skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 .
  • FIG. 15 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin (No. 2-5) in which the top sheet contains tri-C2L oil fatty acid glycerides.
  • the tri-C2L oil fatty acid glyceride is in the form of fine particles and is attached to the fiber surface. According to the above-mentioned procedure, the rewetting rate and the absorber transfer speed were measured. The results are shown in Table 2 below.
  • Rewetting rate (%) 100 ⁇ (filter paper mass after test ⁇ initial filter paper mass) / 6
  • absorption body transfer rate which is the time for blood to transfer from the top sheet to the absorber, was measured after the second drop of blood.
  • absorption body transfer speed means the time from when blood is introduced into the top sheet until the redness of blood is not seen on the surface and inside of the top sheet.
  • the rewetting rate was 22.7% and the absorber transfer rate was more than 60 seconds, but all triesters of glycerin and fatty acids had a rewetting rate. Since it is 7.0% or less and the absorber transfer speed is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among the triesters of glycerin and fatty acid, NA50 having a melting point exceeding 45 ° C. did not significantly improve the absorption performance.
  • a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C. It was found that the absorption performance was greatly improved.
  • No. 2-1 In the 2-32 sanitary napkin, and in particular, no. In the sanitary napkin containing the blood modifying agents of 2-1 to 11, 15 to 19 and 32, the skin contact surface of the top sheet after absorbing menstrual blood is not stained with blood in red, and there is little discomfort And got the answer.
  • Example 2 The rewetting rate was evaluated according to the procedure described above for various animal blood.
  • the blood used in the experiment is as follows. [Animal species] (1) Human (2) Horse (3) Sheep
  • Defibrinated blood After collecting blood, stirred for about 5 minutes in an Erlenmeyer flask with glass beads
  • ⁇ EDTA blood 65 mL of venous blood plus 0.5 mL of 12% EDTA / 2K physiological saline
  • Serum or plasma supernatant after centrifugation of defibrinated blood or EDTA blood at about 1900 G at room temperature for 10 minutes, respectively.
  • Blood cell serum is removed from the blood, and the residue is converted to phosphate buffered saline (PBS ) Washed twice and then added with phosphate buffered saline for the removed serum
  • An absorbent article was produced in the same manner as in Example 2 except that the tri-C2L oil fatty acid glyceride was applied so that the basis weight was approximately 5 g / m 2, and the rewetting rate was evaluated for the various blood types described above. . The measurement was performed 3 times for each blood, and the average value was adopted. The results are shown in Table 3 below.
  • Example 2 The same tendency as the horse EDTA blood obtained in Example 2 was also obtained in human and sheep blood. Similar trends were also observed in defibrinated blood and EDTA blood.
  • Tri C2L oil fatty acid glyceride was applied to the skin contact surface of the top sheet formed from an air-through nonwoven fabric (a composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) using a control seam HMA gun. It is atomized and applied so that the basis weight is approximately 5 g / m 2 . Moreover, the thing which has not apply
  • the top sheet containing a blood modifying agent has low blood retention and can be quickly transferred to an absorber after absorbing blood.
  • Example 4 [Viscosity of blood containing blood modifying agents] The viscosity of blood containing a blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by mass of panacet 810s was added to equine defibrinated blood, lightly stirred to form a sample, the sample was placed on a parallel plate with a diameter of 50 mm, the gap was 100 ⁇ m, and the viscosity was measured at 37 ⁇ 0.5 ° C. . Because of the parallel plate, the sample did not have a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁇ 1 .
  • the viscosity of horse defibrinated blood containing 2% by mass of panacet 810s was 5.9 mPa ⁇ s, while the viscosity of horse defibrinated blood containing no blood modifying agent was 50.4 mPa ⁇ s. Therefore, it can be seen that equine defibrinated blood containing 2% by mass of panacet 810s lowers the viscosity by about 90% compared to the case where no blood modifying agent is contained.
  • blood is known to contain components such as blood cells and have thixotropic properties
  • the blood modifying agent of the present disclosure is considered to be able to lower the viscosity of blood in a low viscosity range. It is considered that the absorbed menstrual blood can be quickly transferred from the top sheet to the absorber by lowering the viscosity of the blood.
  • Example 5 [Micrograph of blood containing blood modifying agent]
  • the menstrual blood of healthy volunteers is collected on Saran Wrap (trademark), and a portion of panacet 810s dispersed in 10 times the mass of phosphate buffered saline is used, so that the concentration of panacet 810s is 1% by mass.
  • Menstrual blood was appropriately applied to a slide glass, covered with a cover glass, and the state of red blood cells was observed with an optical microscope.
  • a photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 16 (a)
  • a photomicrograph of menstrual blood containing panacet 810s is shown in FIG. 16 (b).
  • red blood cells form a collective lump such as remuneration, but in menstrual blood that includes panacet 810s, red blood cells are each stably dispersed. I understand. Therefore, it is suggested that the blood modifying agent functions to stabilize red blood cells in the blood.
  • Example 6 [Surface tension of blood containing blood modifying agents] The surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently. The measurement is automatically performed by the instrument, and the density ⁇ is obtained by the following equation (see FIG. 17).
  • the density ⁇ is defined in 5. of “Density Test Method and Density / Mass / Capacity Conversion Table” of JIS K 2249-1995. Based on the vibration density test method, the temperature was measured as shown in Table 5 below. For measurement, DA-505 of Kyoto Electronics Industry Co., Ltd. was used. The results are shown in Table 5.
  • the blood modifying agent has a water solubility of about 0.00 to about 0.05 g in 100 g of water at 25 ° C., but the solubility in water is very low. It can be seen that the surface tension of blood can be lowered. By reducing the surface tension of the blood, it is considered that the absorbed blood can be quickly transferred to the absorbent body without being held between the fibers of the top sheet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
PCT/JP2013/058590 2012-03-30 2013-03-25 吸収性物品 Ceased WO2013146685A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-082334 2012-03-30
JP2012082334A JP5769655B2 (ja) 2012-03-30 2012-03-30 吸収性物品

Publications (1)

Publication Number Publication Date
WO2013146685A1 true WO2013146685A1 (ja) 2013-10-03

Family

ID=49259936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/058590 Ceased WO2013146685A1 (ja) 2012-03-30 2013-03-25 吸収性物品

Country Status (4)

Country Link
JP (1) JP5769655B2 (enExample)
AR (1) AR090519A1 (enExample)
TW (1) TWI581775B (enExample)
WO (1) WO2013146685A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029024A (zh) * 2014-02-25 2016-10-12 尤妮佳股份有限公司 尿垫以及尿垫收纳件

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6457780B2 (ja) * 2014-10-28 2019-01-23 大王製紙株式会社 吸収性物品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0488932U (enExample) * 1990-06-08 1992-08-03
JPH05154176A (ja) * 1991-12-09 1993-06-22 Kao Corp 生理用ナプキン
JPH11513283A (ja) * 1995-10-06 1999-11-16 ザ、プロクター、エンド、ギャンブル、カンパニー 変形ヒンジ及び伸長性の帯域付きフラップを有する吸収体
JP2010142367A (ja) * 2008-12-17 2010-07-01 Kao Corp 吸収性物品
JP2011510801A (ja) * 2008-02-15 2011-04-07 ザ プロクター アンド ギャンブル カンパニー ポリプロピレングリコール材料を含むローションを備える吸収性物品

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2399915T3 (en) * 2004-03-12 2015-03-09 Vertex Pharma A process and intermediates for the preparation of asparaginacetal-caspase inhibitors
CN101732136B (zh) * 2008-11-13 2014-07-30 花王株式会社 吸收性物品的单个包装体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0488932U (enExample) * 1990-06-08 1992-08-03
JPH05154176A (ja) * 1991-12-09 1993-06-22 Kao Corp 生理用ナプキン
JPH11513283A (ja) * 1995-10-06 1999-11-16 ザ、プロクター、エンド、ギャンブル、カンパニー 変形ヒンジ及び伸長性の帯域付きフラップを有する吸収体
JP2011510801A (ja) * 2008-02-15 2011-04-07 ザ プロクター アンド ギャンブル カンパニー ポリプロピレングリコール材料を含むローションを備える吸収性物品
JP2010142367A (ja) * 2008-12-17 2010-07-01 Kao Corp 吸収性物品

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029024A (zh) * 2014-02-25 2016-10-12 尤妮佳股份有限公司 尿垫以及尿垫收纳件
CN106029024B (zh) * 2014-02-25 2019-08-13 尤妮佳股份有限公司 尿垫以及尿垫收纳件

Also Published As

Publication number Publication date
TWI581775B (zh) 2017-05-11
TW201402086A (zh) 2014-01-16
JP2013208387A (ja) 2013-10-10
AR090519A1 (es) 2014-11-19
JP5769655B2 (ja) 2015-08-26

Similar Documents

Publication Publication Date Title
JP5925015B2 (ja) 吸収性物品
JP5713951B2 (ja) 吸収性物品
JP5847055B2 (ja) 吸収性物品
JP5843740B2 (ja) 吸収性物品
JP5963639B2 (ja) 吸収性物品
JP6037606B2 (ja) 吸収性物品、吸収性物品のトップシートおよびそのトップシートの製造方法
JP5916327B2 (ja) 吸収性物品
JP5709788B2 (ja) 吸収性物品
JP5745377B2 (ja) 吸収性物品
JP5769655B2 (ja) 吸収性物品
JP6041472B2 (ja) 吸収性物品、吸収性物品のトップシートおよびそのトップシートの製造方法
JP5762346B2 (ja) 吸収性物品
JP5709789B2 (ja) 吸収性物品
JP5713950B2 (ja) 吸収性物品
JP5726123B2 (ja) 吸収性物品
WO2013129326A1 (ja) 吸収性物品
WO2013129325A1 (ja) 吸収性物品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13769130

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13769130

Country of ref document: EP

Kind code of ref document: A1